AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02210962 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: olive oil
Description: Yellow capsules containing olive oil (placebo)
Study NCT02916004 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Measurement of NFR and PDR
Description: Feasibility testing of NFR and PDR in sedated, ventilated patients. Comparison of NFR and PDR with standard routine care of pain assessment
Study NCT02394899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Play therapy
Description: Short films that have been developed to deliver a series of child development messages will be shown at the monthly visits. Nine modules of approximate length 3 minutes each have been developed and cover the topics: Love, Comforting baby, Talking to babies and children, Praise, Using bath time to play and learn, Looking at books, Simple toys mothers can make, Drawing and games, and Puzzles. Nurses at the Sickle cell Unit (SCU) will be trained to discuss the video messages with the mothers/caregivers, demonstrate activities they can do with their children and how to make simple toys from household materials. Mothers/caregivers will practice some of the activities and they will be encouraged to make them part of their daily routine.
Study NCT02394899 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Problem solving skills
Description: Problem solving therapy (PST) aims to empower patients or caregivers in attending to daily challenges. It is based on cognitive behavioural therapy and can be used in primary care settings. It encourages persons to use existing resources and skills to function better and find solutions to problems. It will be delivered in 6 sessions over the 6-week period and will last for about 30 minutes per session. The stages of PST are: identification of the problems; generating possible solutions; evaluating and implementing preferred solution; and evaluating to see if the solutions were successful. The parent/caregiver will be taught a process of problem solving with reference to general everyday problems as well as specific problems which may arise while parenting a child with SCD.
Study NCT05015673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP363856
Study NCT05015673 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02773706 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Automated Psychology Services
Description: The automated screening tool determines a positive or negative screen, then informs the clinician, and also automates a psychology visit.
Study NCT02773706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Notification of Subspecialist
Description: The automated screening tool determines a positive or negative screen, then informs the clinician.
Study NCT04387539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOF/SMV/DCV/RBV
Description: SOF was given orally at a dose of 400 mg/day DCV was given orally at a dose of 60 mg/day SMV was given orally at a dose of 150 mg/day. RBV was given in a total daily oral dose of 600 mg/day up to 1,200 mg/day according to the participant's weight and tolerability.
Study NCT01304082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 1 ml subcutaneous injection of 0.9% lidocaine, given once
Study NCT01304082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 1 ml subcutaneous injection 0.9% sodium chloride, given once
Study NCT01304082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alkalinized lidocaine
Description: 1 ml subcutaneous injection of 0.9% lidocaine and 0.84% sodium bicarbonate
Study NCT03049657 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angiolite
Description: Percutaneous coronary intervention
Study NCT03049657 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience
Description: Percutaneous coronary intervention
Study NCT00823732 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: Undergo individualized interdisciplinary palliative care intervention
Study NCT00823732 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: medical chart review
Description: Ancillary studies
Study NCT00823732 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT00823732 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: end-of-life treatment/management
Description: Undergo end-of-life treatment/management
Study NCT00823732 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: psychosocial assessment and care
Description: Undergo psychosocial assessment and care
Study NCT00823732 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT00823732 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: management of therapy complications
Description: Undergo management of therapy complications
Study NCT00823732 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: assessment of therapy complications
Description: Undergo assessment of therapy complications
Study NCT03217734 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Subcutaneous Injection
Study NCT03217734 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Adalimumab
Description: Subcutaneous Injection
Study NCT03217734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Oral Tablet
Study NCT03217734 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Tablet
Study NCT01673360 — intervention group
Intervention type: DEVICE
Intervention: Elevate PC
Description: List of AMS prolapse products
Study NCT01673360 — intervention group
Intervention type: DEVICE
Intervention: Mini Arc Pro
Description: List of AMS Urinary Incontinence devices
Study NCT01673360 — intervention group
Intervention type: DEVICE
Intervention: RetroArc
Description: List of AMS Urinary Incontinence devices
Study NCT01782963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study NCT01782963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Study NCT01782963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT01264029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Tai Chi Intervention
Study NCT01264029 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Meditation
Study NCT01264029 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mall Walking
Study NCT01264029 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weekly Discussion
Study NCT01276249 — intervention group
Intervention type: DEVICE
Intervention: Fortevo Endograft
Description: The Fortevo Endograft, Main Body and Iliac Lumen Delivery System are indicated for the endovascular treatments of patients with infrarenal abdominal aortic aneurysms or aortic-iliac aneurysms having suitable morphology for endovascular repair.
Study NCT00941278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-10 (0.001% Rose Bengal)
Description: PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
Study NCT02838628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg of KX2-391 Ointment 1%
Description: Dose: 50 mg; Route of administration: Topical
Study NCT02397460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant tablets administered orally as a single dose of 50 mg (1 tablet) or 300 mg (6 tablets)
Study NCT02966119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel or Aspirin and/or Dypyridamole
Description: The physician will prescribe on this antiplatelet agent if the patient is randomized in the arm  restart
Study NCT04486469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy Group
Description: 1. Performing direct physical treatment on the diaphragm, using stretching, followed by teaching exercises for re-education of the abdomen and diaphragm.~2. Transcutaneous retrograde electrostimulation: L1-L4 (2hz-10hz) rectangular asymmetric biphasic at the level of the dermatome. From the anterior inferior iliac spine to a pubic symphysis. Second canal from the greater trochanter to the saphenous veins. (30 min). Parameters of this program: 2 Hz and 180ms.~3. Connective Tissue Massage or Dicke~4. Massage with direct maneuvers on the abdomen: The direction of the maneuvers will be clockwise. We will perform 6 very slow strokes adding small pressures on the ascending, transverse and descending colon respectively and repeating this maneuver 3 times. (10 minutes)
Study NCT01122940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epamin: Reference Drug
Description: Single dose of 75 mg (10 ml in suspension) of Epamin
Study NCT01122940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin: Study Drug
Description: Single dose of 75 mg (10 ml in suspension) of Phenytoin
Study NCT04586335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYH33
Description: Clinical Activity of CYH33, an Oral α-specific PI3K Inhibitor in Combination with Olaparib, an Oral PARP Inhibitor
Study NCT03660124 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: DBS is a neurosurgical procedure that involves the administration of small amounts of electricity to disrupt abnormal activity of brain structures associated with disease symptoms. It involves inserting thin electrodes into deep brain structures and electrically stimulating them in a controllable and ultimately reversible manner. The electrodes are connected to an internal pulse generator that is implanted in the upper chest region, below the collarbone.
Study NCT03408223 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total marrow and lymphoid irradiation
Description: Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Marrow and Lymphoid Irradiation Dose of 12-20 Gy TMLI (fraction size of 4 Gy given once a day).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0.
Study NCT02958059 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pacetin® (cefoxitin)
Description: 1\~2g of Cefoxitin (2nd generation cephalosporin) is administered to patients 30 minutes Before ERCP procedure. Cefoxitin is mixed with 10ml of normal saline. Patients and caregivers can not distinguish antibiotics and placebo by naked eye.
Study NCT02958059 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10ml of normal saline is injected to patients as placebo. Patients and caregivers can not distinguish antibiotics and placebo by naked eye.
Study NCT02200978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATO
Description: Given IV
Study NCT02200978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIF
Description: Given orally
Study NCT02200978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATRA
Description: Given orally
Study NCT02200978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRA
Description: Given orally
Study NCT02200978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mitoxantrone
Description: Given IV
Study NCT02200978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone
Description: Given IV
Study NCT04510389 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Bariatric patients with or without sarcopenia receiving maltodextrin
Study NCT04510389 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey
Description: Bariatric patients with or without sarcopenia receiving whey protein
Study NCT04612972 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated SARS CoV 2 vaccine (Vero cell) Wuhan/Beijing/Placebo
Description: This clinical trial is conducted in randomized, blind, placebo controlled design Total sample size is 12 000, which are randomly allocated into investigational vaccine 1, investigational vaccine 2 and placebo control group.
Study NCT04612972 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Inactivated SARS CoV 2 vaccine (Vero cell) Wuhan/Beijing/Placebo
Description: This clinical trial is conducted in randomized, blind, placebo controlled design Total sample size is 12 000, which are randomly allocated into investigational vaccine 1, investigational vaccine 2 and placebo control group.
Study NCT03219905 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Kinesio-taping
Description: The experimental group received a therapeutic Kinesio Tape application. Three I strips were applied to the both ankle joints for joint stability with subject's ankle at 90 degrees.
Study NCT03219905 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Kinesio-taping
Description: The control group received a sham Kinesio Tape application. Ankle position was hold at minimally plantar flexion during taping. AI strip was placed from the anterior midfoot, not stretched and attached to the midline of anterior leg.
Study NCT04115410 — intervention group
Intervention type: DRUG
Intervention: PD-1 inhibitor
Description: PD-1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer. The investigators will include nivolumab, pembrolizumab, and atezolizumab as PD-1 inhibitors as these drugs are reimbursed by health authority of South Korea.
Study NCT04115410 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy Drugs, Cancer
Description: Chemotherapy is a type of pharmacotherapy for cancer, that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen. The investigators will include cytotoxic chemotherapy and tyrosine kinase inhibitors (epidermal growth cell receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors).
Study NCT03557684 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: leucine
Description: amino acid leucine in powder
Study NCT03557684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PO placebo
Description: maltodextrin
Study NCT02200978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ara-C
Description: Given IV
Study NCT02200978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: Given IV
Study NCT02200978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX
Description: Given orally
Study NCT03557684 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PO placebo
Description: maltodextrin
Study NCT03557684 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lipopolysaccharide (LPS)
Description: purified bacterial wall component as an inflammatory challenge
Study NCT03557684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IV placebo
Description: 0.9% saline
Study NCT03557684 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IV placebo
Description: 0.9% saline
Study NCT01398410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Participants received rabeprazole 5 mg tablets and rabeprazole 10 mg matched placebo tablets orally, once daily
Study NCT01398410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Participants received rabeprazole 10 mg tablets and rabeprazole 5 mg matched placebo tablets orally, once daily
Study NCT01276119 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: 100 mg/mL solution for injection Single infusion over 60 minutes
Study NCT01276119 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: 100 mg/mL solution for injection Single infusion over 120 minutes
Study NCT01276119 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: 100 mg/mL solution for injection Single sc injection
Study NCT01276119 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride for injection Single infusion over 60 minutes
Study NCT01276119 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride for injection Single infusion over 120 minutes
Study NCT01276119 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride for injection Single sc injection
Study NCT01656187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine 10 mg capsule
Description: Memantine oral capsule was initiated at 5 mg/day at Randomization (Week 0), then titrated to 5 mg twice a day at Week 2, then increased to 10 mg in the morning and 5 mg in the evening at Week 3, and then to 10 mg twice a day (intervention dose) at Weeks 4-24. For the participants in the Placebo, then Memantine arm, the same titration schedule was maintained after the 4-week washout period (Week 28-52).
Study NCT01656187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine-matched Placebo capsule
Description: Memantine-matched oral Placebo capsule was initiated at Randomization (Week 0) and maintained Weeks 0-24 in a manner consistent with the active drug titration schedule. The number of placebo capsules matched the number of active drug capsules at each titration checkpoint. For the participants in the Memantine, then Placebo arm, the same titration schedule was maintained after the 4-week washout period (Week 28-52).
Study NCT01281267 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Facial Allograft Transplantation
Description: Facial allograft transplantation surgery is the transfer of face tissue from a deceased human donor to a patient with a severe facial deformity.
Study NCT02777281 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Shoulder pain and SCI
Description: Shoulder pain and SCI
Study NCT02777281 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Shoulder pain and able bodies
Study NCT04343053 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: SARS-Cov-2 infection
Description: blood sample withdrawal
Study NCT04665518 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Acupressure will be applied to the patients in the acupressure group for 10 min before the venipuncture procedure. Venipuncuture is applied to all patients by the same nurse in the same room. Venipuncture is performed from the left arm of all patients using a vacuum tube and a needle tip of 0.8 \* 38 mm (21G x 1½, green).
Study NCT03974022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunvozertinib
Description: Daily dose of Sunvozertinib
Study NCT04577534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iv Tocillizumab (TCZ)
Description: Participants are randomized (2:1) to receive TCZ or Standard of Care
Study NCT02758873 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Personalised medicine (Salmeterol)
Description: If participants require add-on medication and have the Gly/Gly variant on the ADRB2, salmeterol will be prescribed.
Study NCT02758873 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Personalised medicine (Montelukast)
Description: If participants require add-on medication and have the Arg/Arg or Arg/Gly variant on the ADRB2, montelukast will be prescribed.
Study NCT02758873 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: If participants require add-on medication in the arm, they will be prescribed either salmeterol or montelukast according to health professional's choice based on current guidelines.
Study NCT00438256 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation
Description: Given over different schedules and duration
Study NCT00438256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given orally starting on day one of radiation therapy for 2 weeks
Study NCT03050112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MacNew questionnaire
Description: Patients will be asked to fill in the MacNew questionnaire on quality of life (phone contact).
Study NCT00388297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.
Study NCT00388297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Levothyroxine